Medtech in May: market surveillance movements, reimbursement and fees reimbursement make Clinica’s top 10
This article was originally published in Clinica
During the month of May, trends in reporting activities by competent authorities captured the most attention from Clinica’s readers. The month’s most-read article reported the surprise downturn in the number of reports exchanged between these EU bodies; given the effort at tighter enforcement and better communication between competent authorities, this was unexpected. But does it suggest that the tougher environment now emerging as a result of the commission medtech immediate joint action plan - launched in 2012 - is actually working and fewer events are occurring?
You may also be interested in...
Non-CE-marked products on the EU market, virtual notified body audits, free standards and the Commission bid to pause the MDR. March has seen unprecedented developments as COVID-19 has railroaded through the sector decimating regulatory rules and plans.
Suppliers to the UK’s National Health Service from outside the EU could save up to 12% in costs for some equipment during COVID-19 emergency measures as the UK tries to increase supplies
While the UK is moving forward quickly to provide COVID-19 antibody self-testing, the Belgian government considers the tests not sufficiently accurate to be used in the pandemic.